Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics (XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to a new employee. The inducement grant includes options to purchase 5,000 shares of common stock at an exercise price of $0.755 per share, equal to the closing price on May 1, 2025. The options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting monthly over three years. This grant was made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (XLO), un'azienda biotecnologica in fase clinica specializzata in terapie immuno-oncologiche attivate dai tumori, ha assegnato opzioni su azioni a un nuovo dipendente. L'incentivo prevede opzioni per l'acquisto di 5.000 azioni ordinarie al prezzo di esercizio di 0,755 $ per azione, corrispondente al prezzo di chiusura del 1° maggio 2025. Le opzioni hanno una durata di dieci anni con un piano di maturazione del 25% dopo il primo anno e il restante 75% che matura mensilmente nel corso di tre anni. Questa assegnazione è stata effettuata nell'ambito del Piano di Incentivazione Azionaria 2022 di Xilio, in conformità con la Regola 5635(c)(4) del Nasdaq.
Xilio Therapeutics (XLO), una empresa biotecnológica en etapa clínica enfocada en terapias inmuno-oncológicas activadas por tumores, ha otorgado opciones sobre acciones a un nuevo empleado. La concesión de incentivos incluye opciones para comprar 5,000 acciones ordinarias a un precio de ejercicio de $0.755 por acción, igual al precio de cierre del 1 de mayo de 2025. Las opciones tienen un plazo de diez años con un calendario de adquisición del 25% después del primer año y el 75% restante que se adquiere mensualmente durante tres años. Esta concesión se realizó bajo el Plan de Incentivos de Acciones por Inducción 2022 de Xilio, conforme a la Regla 5635(c)(4) de Nasdaq.
Xilio Therapeutics (XLO)는 종양 활성화 면역항암 치료제에 중점을 둔 임상 단계의 생명공학 회사로서, 신규 직원에게 주식 매수 선택권을 부여했습니다. 이 유인 보조금은 5,000주의 보통주를 주당 $0.755의 행사 가격으로 구매할 수 있는 옵션을 포함하며, 이는 2025년 5월 1일 종가와 동일합니다. 옵션의 유효 기간은 10년이며, 1년 후 25%가 베스팅되고 나머지 75%는 3년에 걸쳐 매월 베스팅됩니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 Xilio의 2022년 유인 주식 인센티브 계획에 따라 이루어졌습니다.
Xilio Therapeutics (XLO), une société biotechnologique en phase clinique spécialisée dans les thérapies immuno-oncologiques activées par les tumeurs, a accordé des options d'achat d'actions à un nouvel employé. Cette attribution d'incitation comprend des options d'achat de 5 000 actions ordinaires à un prix d'exercice de 0,755 $ par action, égal au cours de clôture du 1er mai 2025. Les options ont une durée de dix ans avec un calendrier d'acquisition de 25 % après la première année et les 75 % restants acquis mensuellement sur trois ans. Cette attribution a été effectuée dans le cadre du Plan d'Incitation à l'Attribution d'Actions 2022 de Xilio, conformément à la règle 5635(c)(4) du Nasdaq.
Xilio Therapeutics (XLO), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf tumoraktivierte Immunonkologie-Therapien spezialisiert hat, hat einem neuen Mitarbeiter Aktienoptionen gewährt. Der Anreiz umfasst Optionen zum Kauf von 5.000 Stammaktien zu einem Ausübungspreis von 0,755 $ pro Aktie, entsprechend dem Schlusskurs vom 1. Mai 2025. Die Optionen haben eine Laufzeit von zehn Jahren mit einem Vesting-Zeitplan von 25 % nach dem ersten Jahr und den verbleibenden 75 %, die monatlich über drei Jahre hinweg vesten. Diese Gewährung erfolgte im Rahmen des Inducement Stock Incentive Plans 2022 von Xilio gemäß Nasdaq Listing Rule 5635(c)(4).
- None.
- None.
WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
The stock options have an exercise price of
The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Investor and Media Contact:
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
FAQ
What stock options did Xilio Therapeutics (XLO) grant to its new employee in May 2025?
What is the vesting schedule for XLO's May 2025 inducement stock options?
What is the exercise price for Xilio Therapeutics' May 2025 inducement grant?
Under which plan were XLO's May 2025 stock options granted?
